Novo Sues Sun Pharma Twice to Block Copies of Saxenda, Victoza

Novo Nordisk AS filed two lawsuits alleging that Sun Pharmaceutical Industries Ltd.’s proposed generic versions of Novo’s injectable weight-loss treatment Saxenda and the blockbuster diabetes drug Victoza respectively infringe 19 and four patents, according to filings in Delaware federal court.

The Saxenda complaint—which like the Victoza suit was filed July 1 in the US District Court for the District of Delaware—includes a patent that covers a method for using liraglutide, Saxenda’s active ingredient, to reduce the development of a major adverse cardiovascular event. That patent expires in July 2037, the latest expiration of Victoza patents listed in the US ...